Secondary progressive multiple sclerosis: a systematic review of costs and health state utilities

References

• Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278–286.
   PubMed Web of Science ®Google Scholar
• Scalfari A, Neuhaus A, Daumer M, et al. Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;85(1):67–75.
   PubMed Web of Science ®Google Scholar
• Callegaro D, Goldbaum M, Morais L, et al. The prevalence of multiple sclerosis in the city of São Paulo, Brazil, 1997. Acta Neurol Scand. 2001;104(4):208–213.
   PubMed Web of Science ®Google Scholar
• Visser EM, Wilde K, Wilson JF, et al. A new prevalence study of multiple sclerosis in Orkney, Shetland and Aberdeen city. J Neurol Neurosurg Psychiatry. 2012;83(7):719–724.
   PubMed Web of Science ®Google Scholar
• Simpson S Jr, Blizzard L, Otahal P, et al. Latitude is significantly associated with the prevalence of multiple sclerosis: a meta-analysis. J Neurol Neurosurg Psychiatry. 2011;82(10):1132–1141.
   PubMed Web of Science ®Google Scholar
• Atlas of MS. 2013. Mapping multiple sclerosis around the world. [cited 2021 Feb 8]. Available from: https://www.msif.org/wp-content/uploads/2014/09/Atlas-of-MS.pdf
   Google Scholar
• Katz Sand I, Krieger S, Farrell C, et al. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler. 2014;20(12):1654–1657.
   PubMed Web of Science ®Google Scholar
• Lorscheider J, Buzzard K, Jokubaitis V, et al. Defining secondary progressive multiple sclerosis. Brain. 2016;139(Pt 9):2395–2405.
   PubMed Web of Science ®Google Scholar
• Bencsik K, Rajda C, Fuvesi J, et al. The prevalence of multiple sclerosis, distribution of clinical forms of the disease and functional status of patients in Csongrád County, Hungary. Eur Neurol. 2001;46(4):206–209.
   PubMed Web of Science ®Google Scholar
• Gross HJ, Watson C. Characteristics, burden of illness, and physical functioning of patients with relapsing-remitting and secondary progressive multiple sclerosis: a cross-sectional US survey. NDT. 2017;13:1349–1357.
   Web of Science ®Google Scholar
• Papachilleos S, Katsavos S, Evangelopoulos ME, et al. Prevalence of bladder dysfunction in patients with multiple sclerosis [Conference Abstract]. J Neurol. 2012;1:S154.
   Google Scholar
• Pike J, Watson C, Naoshy S, et al. Patient-reported symptom burden among relapsing remitting multiple sclerosis (RRMS) vs secondary progressive multiple sclerosis patients (SPMS) in Europe [Conference Abstract]. Eur J Neurol. 2015;22:255.
   Web of Science ®Google Scholar
• Mohammadi K, Rahnama P, Mohseni SM, et al. Determinants of sexual dysfunction in women with multiple sclerosis. BMC Neurol. 2013;13(1):83.
   PubMed Web of Science ®Google Scholar
• Achiron A, Chapman J, Magalashvili D, et al. Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional study. PLoS One. 2013 01;8(8):e71058. Aug
   PubMed Web of Science ®Google Scholar
• Huijbregts SC, Kalkers NF, de Sonneville LM, et al. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS. Neurology. 2004;63(2):335–339.
   PubMed Web of Science ®Google Scholar
• Mellion M, Brochet B, Nocentini U, et al. Characterization of baseline cognitive profiles of RRMS and SPMS patients in international multiple sclerosis clinical trials utilizing MS-COG [Conference Abstract]. Multiple Sclerosis. 2015;1:120–121.
   Google Scholar
• Bhatia R, Singh N. Can we treat secondary progressive multiple sclerosis now? Ann Indian Acad Neurol. 2019;22(2):131–136.
   PubMed Web of Science ®Google Scholar
• Doshi A, Chataway J. Multiple sclerosis, a treatable disease. Clin Med (Lond). 2016;16(Suppl 6):s53–s59.
   PubMedGoogle Scholar
• Ara R, Brazier J, Zouraq IA. The use of health state utility values in decision models. Pharmacoeconomics. 2017;35(Suppl 1):77–88.
   PubMed Web of Science ®Google Scholar
• Ara R, Brazier J, Peasgood T, et al. The identification, review and synthesis of health state utility values from the literature. Pharmacoeconomics. 2017;35(Suppl 1):43–55.
   PubMed Web of Science ®Google Scholar
• Ara R, Peasgood T, Mukuria C, et al. Sourcing and using appropriate health state utility values in economic models in health care. Pharmacoeconomics. 2017;35(Suppl 1):7–9.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
   PubMed Web of Science ®Google Scholar
• Shemilt I, Thomas J, Morciano M. A web-based tool for adjusting costs to a specific target currency and price year. Evidence and Policy. 2010;6(1):51–59.
   Web of Science ®Google Scholar
• Campbell and Cochrane Economics Methods Group. EPPI-Centre Cost Converter. v1.6. [2019 Apr 26; cited 2021 Jan 13]. Available from: https://eppi.ioe.ac.uk/costconversion/#:∼:text=The%20'CCEMG%20%E2%80%93%20EPPI%2DCentre,target%20currency%20and%20price%20year
   Google Scholar
• McCrone P, Heslin M, Knapp M, et al. Multiple sclerosis in the UK: service use, costs, quality of life and disability. Pharmacoeconomics. 2008;26(10):847–860.
   PubMed Web of Science ®Google Scholar
• Gyllensten H, Kavaliunas A, Murley C, et al. Costs of illness progression for different multiple sclerosis phenotypes: a population-based study in Sweden. Mult Scler J Exp Transl Clin. 2019;5(2):2055217319858383.
   Google Scholar
• Reese JP, John A, Wienemann G, et al. Economic burden in a German cohort of patients with multiple sclerosis. Eur Neurol. 2011;66(6):311–321.
   PubMed Web of Science ®Google Scholar
• Patti F, Amato MP, Trojano M, et al. Multiple sclerosis in Italy: cost-of-illness study. Neurol Sci. 2011;32(5):787–794.
   PubMed Web of Science ®Google Scholar
• Carney P, O'Boyle D, Larkin A, et al. Societal costs of multiple sclerosis in Ireland. J Med Econ. 2018;21(5):425–437.
   PubMed Web of Science ®Google Scholar
• Amato MP, Battaglia MA, Caputo D, et al. The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy. J Neurol. 2002;249(2):152–163. Feb
   PubMed Web of Science ®Google Scholar
• Johansson E, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from France. Mult Scler. 2012;18(2 Suppl):17–22.
   PubMed Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Spain. Mult Scler. 2012;18(2 Suppl):35–39.
   PubMed Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Germany. Mult Scler. 2012;18(2 Suppl):23–27.
   PubMed Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from Italy. Mult Scler. 2012;18(2 Suppl):29–34.
   PubMed Web of Science ®Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from the United Kingdom. Mult Scler. 2012;18(2 Suppl):41–45.
   PubMed Web of Science ®Google Scholar
• Fogarty E, Walsh C, McGuigan C, et al. Direct and indirect economic consequences of multiple sclerosis in Ireland. Appl Health Econ Health Policy. 2014;12(6):635–645.
   PubMedGoogle Scholar
• Taylor B, McDonald E, Fantino B, et al. The cost of multiple sclerosis in Australia. J Clin Neurosci. 2007;14(6):532–539.
   PubMed Web of Science ®Google Scholar
• Bruno D, Marc D, Ouarda P, et al. Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims. Mult Scler Relat Disord. 2019;36:101396.
   PubMed Web of Science ®Google Scholar
• Moccia M, Tajani A, Acampora R, et al. Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery. PLoS One. 2019;14(9):e0222012.
   PubMed Web of Science ®Google Scholar
• Purmonen T, Hakkarainen T, Tervomaa M, et al. Impact of multiple sclerosis phenotypes on burden of disease in Finland. J Med Econ. 2020;23(2):156–165.
   PubMed Web of Science ®Google Scholar
• Blinkenberg M, Kjellbjerg J, Ibsen R, et al. Increased socioeconomic burden in patients with primary progressive multiple sclerosis: a Danish nationwide population-based study [poster]. Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis and 24th Annual Conference of Rehabilitation in MS; 11–13 September 2019; Stockholm, Sweden.
   Google Scholar
• Ness N-H, Schriefer D, Haase R, et al. Societal economic impact of disability progression independent of relapse activity: a real world longitudinal analysis in patients with multiple sclerosis [poster]. Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis and 24th Annual Conference of Rehabilitation in MS; 11–13 September 2019; Stockholm, Sweden.
   Google Scholar
• Eriksson J, Kobelt G, Gannedahl M, et al. Association between disability, cognition, fatigue, EQ-5D-3L domains, and utilities estimated with different Western European value sets in patients with multiple sclerosis. Value Health. 2019;22(2):231–238.
   PubMed Web of Science ®Google Scholar
• Hawton A, Green C. Health utilities for multiple sclerosis. Value Health. 2016;19(4):460–468.
   PubMed Web of Science ®Google Scholar
• Orme M, Kerrigan J, Tyas D, et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health. 2007;10(1):54–60.
   PubMed Web of Science ®Google Scholar
• Reese JP, Wienemann G, John A, et al. Preference-based health status in a German outpatient cohort with multiple sclerosis. Health Qual Life Outcomes. 2013;11:162.
   PubMed Web of Science ®Google Scholar
• Rooney S, Wood L, Moffat F, et al. Prevalence of fatigue and its association with clinical features in progressive and non-progressive forms of Multiple Sclerosis. Mult Scler Relat Disord. 2019;28:276–282.
   PubMed Web of Science ®Google Scholar
• Takemoto ML, Lopes da Silva N, Ribeiro-Pereira AC, et al. Differences in utility scores obtained through Brazilian and UK value sets: a cross-sectional study. Health Qual Life Outcomes. 2015;13:119.
   PubMed Web of Science ®Google Scholar
• Tinelli M, Kanavos P, Efthymiadou O, et al. Using IMPrESS to guide policy change in multiple sclerosis. Mult Scler. 2018;24(9):1251–1255.
   PubMed Web of Science ®Google Scholar
• Eriksson M, Andersen O, Runmarker B. Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler. 2003;9(3):260–274.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Thompson A, Berg J, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23(8):1123–1136.
   PubMed Web of Science ®Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095–1108.
   PubMed Web of Science ®Google Scholar
• Beier M, Amtmann D, Ehde DM. Beyond depression: predictors of self-reported cognitive function in adults living with MS. Rehabil Psychol. 2015;60(3):254–262.
   PubMed Web of Science ®Google Scholar
• Blair M, Gill S, Gutmanis I, et al. The mediating role of processing speed in the relationship between depressive symptoms and cognitive function in multiple sclerosis. J Clin Exp Neuropsychol. 2016;38(7):782–794.
   PubMed Web of Science ®Google Scholar
• Lloyd A, Schofield H, Adlard N. Cognitive decline may not be adequately captured in economic evaluations of multiple sclerosis: are new treatments being undervalued? Curr Med Res Opin. 2020;36(4):609–611.
   PubMed Web of Science ®Google Scholar